Selpercatinib 40 mg, 80 mg, 160 mg Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 40 mg, 80 mg, 160 mg
Reference Brands: Retevmo (USA)
Category: Oncology Cancer Care
Selpercatinib is a Oncology Cancer Care product available as Capsules in strengths 40 mg, 80 mg, 160 mg. It corresponds to the reference brand Retevmo (USA). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.
Manufacture or export Selpercatinib? List it or send an offer →
Product Description:
Selpercatinib is an oral targeted therapy used for the treatment of cancers with specific RET gene alterations and is marketed under the brand name Retevmo. It is indicated for adults with RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancers, as well as for children aged 2 years and older with certain solid tumors harboring RET alterations. Treatment with selpercatinib requires prior confirmation of a RET gene mutation or fusion through laboratory genetic testing.
Selpercatinib is a selective tyrosine kinase inhibitor that works by blocking the activity of RET proteins produced by abnormal RET genes. By inhibiting these signaling pathways, it prevents cancer cells from growing and dividing, thereby slowing tumor progression. Its targeted mechanism allows for precise therapy in patients whose cancers are driven by RET alterations, minimizing effects on normal cells.
Taken orally in capsule form, selpercatinib offers a convenient administration route while providing a precision oncology approach. It is being studied for other types of RET-driven cancers as well, expanding its potential use. Selpercatinib represents an important option in the personalized treatment of cancers driven by RET gene abnormalities.
Also known as: selpercatinib (Spanish, French, Italian), selpercatinibe (Portuguese), Selpercatinib (German), селперкатиниб (Russian), سيلبيركاتينيب (Arabic), セルペルカチニブ (Japanese).
Selpercatinib — third party manufacturing & bulk supply
Selpercatinib 40 mg, 80 mg, 160 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Selpercatinib is supplied as Capsules — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Selpercatinib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Selpercatinib →Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.
Frequently Asked Questions
Selpercatinib is used for the treatment of RET fusion-positive non-small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancers in patients with confirmed RET gene alterations.
Selpercatinib is a synthetically manufactured small-molecule kinase inhibitor targeting RET-driven oncogenic signaling.
The trade name of selpercatinib is Retevmo.
Retevmo is developed and marketed by Eli Lilly and Company.
The generic name of Selpercatinib is selpercatinib.
The brand name of Selpercatinib is Retevmo.
Selpercatinib oral capsules are manufactured in GMP-compliant pharmaceutical facilities, primarily in the USA and EU, depending on market distribution.
El selpercatinib es un inhibidor selectivo de la cinasa RET que se toma por vía oral para tratar el cáncer de pulmón no microcítico con fusión de RET, el cáncer medular de tiroides con mutación de RET y otros cánceres de tiroides o tumores sólidos con fusión de RET, según las indicaciones aprobadas en cada país. Se usa con receta, bajo la supervisión de un oncólogo y después de confirmar la alteración de RET con una prueba validada. En PharmaTradz, importadores autorizados, distribuidores y hospitales encuentran selpercatinib de fabricantes con certificación GMP.
O selpercatinibe é um inibidor seletivo da quinase RET, de uso oral, indicado para o câncer de pulmão de células não pequenas com fusão do gene RET, o câncer medular de tireoide com mutação de RET e outros cânceres de tireoide ou tumores sólidos com fusão de RET, conforme as indicações aprovadas em cada país. É usado sob prescrição e supervisão de um oncologista, após a confirmação da alteração de RET por teste validado. Por meio da PharmaTradz, importadores licenciados, distribuidores e hospitais podem obter selpercatinibe de fabricantes com certificação GMP.
Le selpercatinib est un inhibiteur sélectif de la kinase RET pris par voie orale pour traiter le cancer bronchique non à petites cellules avec fusion de RET, le cancer médullaire de la thyroïde avec mutation de RET et d'autres cancers de la thyroïde ou tumeurs solides avec fusion de RET, selon les indications autorisées dans chaque pays. Il est utilisé sur ordonnance, sous la surveillance d'un oncologue, après confirmation de l'altération de RET par un test validé. PharmaTradz accompagne les importateurs agréés, les distributeurs et les hôpitaux dans leur approvisionnement en selpercatinib auprès de fabricants certifiés GMP.
Related Products
Revumenib
Strength:
25 mg, 110 mg, 160 mg
Form: Tablets
Reference Brands: Revuforj (USA)
View Details
Entrectinib
Strength:
100 mg, 200 mg
Form: Capsules
Reference Brands: Rozlytrek (USA/EU)
View Details
Bortezomib 3.5 mg Injection
Strength:
3.5 mg/vial
Form: Injection
Reference Brands: Velcade (USA/EU)
View Details
Bosutinib
Strength:
100 mg, 400 mg, 500 mg
Form: Tablets
Reference Brands: Bosulif (USA)
View Details
Usually answered within 48 hours | GMP documents shared before you commit
